Clinical Trial

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2025 (before its estimated January 27, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is an open-label, multi-centre, single-arm, phase I clinical study, to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of IMM2510 (an anti-PD-L1/VEGF bispecific antibody fusion protein) + IMM27M (a humanized Fc-engineered anti-CTLA-4 antibody) combination therapy in patients with advanced solid tumors.
Trial Details
NCT Number NCT06764836
Lead Sponsor ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Conditions Advanced Solid Tumors, HCC
Enrollment 108 participants
Start Date 2024-07-23
Primary Completion 2026-01-27 (estimated)
Study Completion 2026-01-27 (estimated)
Updated on ClinicalTrials.gov 2025-01-08